These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 10681078

  • 1. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
    Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K.
    Arch Neurol; 2000 Feb; 57(2):205-8. PubMed ID: 10681078
    [Abstract] [Full Text] [Related]

  • 2. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J.
    Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
    [Abstract] [Full Text] [Related]

  • 3. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF.
    Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
    [Abstract] [Full Text] [Related]

  • 4. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K.
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [Abstract] [Full Text] [Related]

  • 5. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [Abstract] [Full Text] [Related]

  • 6. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls.
    Linke R, Gostomzyk J, Hahn K, Tatsch K.
    Eur J Nucl Med; 2000 Dec; 27(12):1809-12. PubMed ID: 11189944
    [Abstract] [Full Text] [Related]

  • 9. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.
    J Neurol Sci; 2001 Jun 15; 187(1-2):55-9. PubMed ID: 11440745
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls.
    Eisensehr I, Linke R, Tatsch K, Kharraz B, Gildehaus JF, Wetter CT, Trenkwalder C, Schwarz J, Noachtar S.
    Sleep; 2003 Aug 01; 26(5):507-12. PubMed ID: 12938802
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerré JP, Baulieu JL.
    J Nucl Med; 2003 May 01; 44(5):663-70. PubMed ID: 12732666
    [Abstract] [Full Text] [Related]

  • 16. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE, Lee WY, Choe YS, Kim JH.
    Neurol Res; 1999 Apr 01; 21(3):255-61. PubMed ID: 10319333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?
    Linke R, Eisensehr I, Wetter TC, Gildehaus FJ, Pöpperl G, Trenkwalder C, Noachtar S, Tatsch K.
    Mov Disord; 2004 Oct 01; 19(10):1158-62. PubMed ID: 15390076
    [Abstract] [Full Text] [Related]

  • 20. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
    Asenbaum S, Brücke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wöber C, Müller C, Deecke L.
    J Nucl Med; 1997 Jan 01; 38(1):1-6. PubMed ID: 8998140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.